03-02-2015] The Food and Drug Administration (FDA) is advising consumers not to purchase or use Hard Wang, a product promoted for sexual enhancement. This product was identified by FDA during an examination of international mail shipments. FDA laboratory analysis confirmed that Hard Wang contains sildenafil, the active ingredient in the FDA approved prescription drug Viagra, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.
Frost Group beneficially owns 20,091,062 shares of Common Stock. The 20,091,062 shares of Common Stock beneficially owned by Frost Group constitute approximately 4.5% of the Issuer’s outstanding shares of Common Stock, based upon 450,091,969 shares of Common Stock outstanding as of January 31, 2015 and calculated in accordance with Rule 13d-3. Frost Group shares the power to vote and the power to dispose such shares with Gamma Trust and Dr. Frost.
Gamma Trust directly beneficially owns 154,359,797 shares of Common Stock. Also, Gamma Trust, as the controlling member of Frost Group, may be deemed to beneficially own the 20,091,062 shares of Common Stock beneficially owned by Frost Group. The 174,450,859 total shares of Common Stock beneficially owned by Gamma Trust constitute 38.8% of the Issuer’s outstanding shares of Common Stock, based upon 450,091,969 shares of Common Stock outstanding as of January 31, 2015, and calculated in accordance with Rule 13d-3. Dr. Frost is the sole trustee of Gamma Trust and holds sole voting and dispositive power with respect to 154,359,797 shares of Common Stock. Gamma Trust has shared voting and dispositive power with respect to the 20,091,062 shares of Common Stock owned by Frost Group.
In addition, the Phillip and Patricia Frost Philanthropic Foundation, Inc., which is controlled by Dr. Frost and his wife, has 2,851,830 shares of OPKO Common Stock. Dr. Frost also has 1,056,574 options to purchase the Company’s Common Stock, which are exercisable within 60 days of this filing and directly beneficially owns 2,012,377 shares of the Company’s Common Stock. Dr. Frost, as the sole trustee of Gamma Trust, which is the controlling member of Frost Group, may be deemed to beneficially own the 20,091,062 shares of Common Stock beneficially owned by Frost Group and the 154,359,797 shares of Common Stock beneficially owned by Gamma Trust. The 180,371,640 shares of Common Stock beneficially owned by Dr. Frost constitute 40% of the Issuer’s
rotating statements made by various company executives shown as inserts on Inovio website
“Inovio’s clinical results to date show universal responses against unmatched virus strains and best-ever T-cell immune responses induced by a non-replicating vaccine. These desirable characteristics could have significant implications for various diseases and we now have multiple human studies progressing.”
“EMC is establishing a solid foundation for the future, while also delivering near-term growth as we transform our business. Thanks to the unified team effort, in 2014 EMC grew revenue and EPS, gained share, increased our dividend and accelerated our buyback program - returning
why would you think LC will write another scathing article if you don't think they really care anymore since they currently have no short position in OPK?
pro"drugs" have been around for a while. OPKO patent is related to a pro"hormone" see Uncletlzz OPKO Due Diligence for more details
United States Patent 8,906,410
Bishop, et al. December 9, 2014
Assignee: Opko Health, Inc.
From the background information supplied by the inventors, news correspondents obtained the following quote: "The Vitamin D metabolites known as 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3 (collectively referred to as '25-hydroxyvitamin D') are fat-soluble steroid prohormones to Vitamin D hormones that contribute to the maintenance of normal levels of calcium and phosphorus in the bloodstream. The prohormone 25-hydroxyvitamin D.sub.2 is produced from Vitamin D.sub.2 (ergocalciferol) and 25-hydroxyvitamin D.sub.3 is produced from Vitamin D.sub.3 (cholecalciferol) primarily by one or more enzymes located in the liver. The two prohormones also can be produced outside of the liver from Vitamin D.sub.2 and Vitamin D.sub.3 (collectively referred to as 'Vitamin D') in certain cells, such as enterocytes, which contain enzymes identical or similar to those found in the liver.
"The prohormones are further metabolized in the kidneys into potent hormones. The prohormone 25-hydroxyvitamin D.sub.2 is metabolized into a hormone known as 1.alpha.,25-dihydroxyvitamin D.sub.3; likewise, 25-hydroxyvitamin D.sub.3 is metabolized into 1.alpha.,25-dihydroxyvitamin D.sub.3 (calcitriol). Production of these hormones from the prohormones also can occur outside of the kidney in cells which contain the required enzyme(s). ...
To me it says a lot about the trade profit when a block for over $1.6M is sold at the ask bid at any time when it’s the lowest trade of the day.
my wife keeps asking me why I just can't drill for more oil since it's so plentiful?
I agree. I already crossed off the gifts I planned to buy for my family with the dividend.